Abstract
Pneumonia is the second leading cause of hospitalization in the United States, and along with influenza is the 8th leading cause of death. The risk of death during a pneumonia-related hospitalization is significantly higher than from many other major causes of hospitalization, as in 2005 it caused 4.6 deaths per 100 discharges. Recent studies have suggested that the use of statins may lead to better outcomes for subjects hospitalized with pneumonia or other infectious diseases. In this article, we examine the possible underlying mechanisms that may result in a beneficial effect of statins on infectious diseases, and describe the existing research that has examined this association. Further studies are needed to determine whether the long-term use of statins for cardioprotective effects also provides protection for patients at risk for pneumonia, or may serve as an acute treatment for pneumonia patients who require hospitalization.
Keywords: HMG-CoA reductase inhibitor, pneumonia
Current Respiratory Medicine Reviews
Title: The Potential Role of Statins in Pneumonia
Volume: 6 Issue: 3
Author(s): Brandy Nakashima, Marcos I. Restrepo, Antonio Anzueto and Eric M. Mortensen
Affiliation:
Keywords: HMG-CoA reductase inhibitor, pneumonia
Abstract: Pneumonia is the second leading cause of hospitalization in the United States, and along with influenza is the 8th leading cause of death. The risk of death during a pneumonia-related hospitalization is significantly higher than from many other major causes of hospitalization, as in 2005 it caused 4.6 deaths per 100 discharges. Recent studies have suggested that the use of statins may lead to better outcomes for subjects hospitalized with pneumonia or other infectious diseases. In this article, we examine the possible underlying mechanisms that may result in a beneficial effect of statins on infectious diseases, and describe the existing research that has examined this association. Further studies are needed to determine whether the long-term use of statins for cardioprotective effects also provides protection for patients at risk for pneumonia, or may serve as an acute treatment for pneumonia patients who require hospitalization.
Export Options
About this article
Cite this article as:
Nakashima Brandy, I. Restrepo Marcos, Anzueto Antonio and M. Mortensen Eric, The Potential Role of Statins in Pneumonia, Current Respiratory Medicine Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339810791526193
DOI https://dx.doi.org/10.2174/157339810791526193 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery The Role of Trimetazidine After Acute Myocardial Infarction
Current Vascular Pharmacology Leptin Signaling in Blood Platelets as a Target for Therapeutic Intervention
Current Signal Transduction Therapy The Potential of Lifestyle Changes for Improving the Clinical Outcome of Patients with Coronary Heart Disease: Mechanisms of Benefit and Clinical Results
Reviews on Recent Clinical Trials Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The role of the COMPASS Strategy
Current Cardiology Reviews M-Protein-derived Conformational Peptide Epitope Vaccine Candidate against Group A Streptococcus
Current Drug Delivery The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Risk Factors for Upper GI Damage in Low-Dose Aspirin Users and the Interaction Between <i>H. pylori</i> Infection and Low-Dose Aspirin Use
Current Pharmaceutical Design Homeobox Genes and Human Genetic Disorders
Current Molecular Medicine The Contribution of Mannose Binding Lectin to Reperfusion Injury after Ischemic Stroke
Current Neurovascular Research Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design Green Tea Attenuates Cardiovascular Remodeling and Metabolic Symptoms in High Carbohydrate-Fed Rats
Current Pharmaceutical Biotechnology Practical Recommendations for Familial Combined Hyperlipidemia Diagnosis and Management: An Update
Vascular Disease Prevention (Discontinued) Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Dopamine: Agonists and Neurodegenerative Disorders
Current Drug Targets Vitamin D and Stroke: Promise for Prevention and Better Outcome
Current Vascular Pharmacology Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage Score For Predicting Outcome
Current Neurovascular Research Genetic and Environmental Determinants of Early Vascular Ageing (EVA)
Current Vascular Pharmacology Targeting Cardiac Mast Cells: Pharmacological Modulation of the Local Renin-Angiotensin System
Current Pharmaceutical Design